

BSP53763AWO_ST25.txt
SEQUENCE LISTING

<110> Bayer Schering Pharma Aktiengesellschaft
<120> Use of a radioactively labelled molecule specifically binding to
ED-B fibronectin in a method of treatment of Hodgkin lymphoma
<130> 53763APCT
<150> EP 08075485.6
<151> 2008-05-08
<150> US 61/051,500
<151> 2008-05-08
<160> 12
<170> PatentIn version 3.3
<210> 1
<211> 116
<212> PRT
<213> Artificial
<220>
<223> Vh of L19
<400> 1

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
20 25 30

Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ser Ile Ser Gly Ser Ser Gly Thr Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Pro Phe Pro Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110

Thr Val Ser Ser
115

<210> 2
<211> 108
<212> PRT
<213> Artificial

<220>
<223> V1 of L19

BSP53763AWO_ST25.txt

<400> 2

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
20 25 30

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

Ile Tyr Tyr Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Gly Arg Ile Pro
85 90 95

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 3

<211> 12

<212> PRT

<213> Artificial

<220>

<223> Linker between Vh and Vl

<400> 3

Gly Asp Gly Ser Ser Gly Gly Ser Gly Gly Ala Ser
1 5 10

<210> 4

<211> 116

<212> PRT

<213> Artificial

<220>

<223> etaCH4 domain

<400> 4

Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp
1 5 10 15

Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe
20 25 30

Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu
35 40 45

Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser
Seite 2

50

55

Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu
65 70 75 80

Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro
85 90 95

Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Glu Ser Ser Arg
100 105 110

Arg Gly Gly Cys
115

<210> 5
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Linker (L19 and etaCH4)

<400> 5

Ser Gly Gly Ser Gly
1 5

<210> 6
<211> 5
<212> PRT
<213> Artificial

<220>
<223> CDR1 Vh

<400> 6

Ser Phe Ser Met Ser
1 5

<210> 7
<211> 17
<212> PRT
<213> Artificial

<220>
<223> CDR2 Vh

<400> 7

Ser Ile Ser Gly Ser Ser Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> 8
<211> 7
<212> PRT

<213> Artificial

<220>

<223> CDR3 VH

<400> 8

Pro Phe Pro Tyr Phe Asp Tyr
1 5

<210> 9

<211> 12

<212> PRT

<213> Artificial

<220>

<223> CDR1 V1

<400> 9

Arg Ala Ser Gln Ser Val Ser Ser Ser Phe Leu Ala
1 5 10

<210> 10

<211> 7

<212> PRT

<213> Artificial

<220>

<223> CDR2 V1

<400> 10

Tyr Ala Ser Ser Arg Ala Thr
1 5

<210> 11

<211> 9

<212> PRT

<213> Artificial

<220>

<223> CDR3 V1

<400> 11

Gln Gln Thr Gly Arg Ile Pro Pro Thr
1 5

<210> 12

<211> 357

<212> PRT

<213> Artificial

<220>

<223> L19-SIP monomer

<400> 12

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
Seite 4

Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ser Ile Ser Gly Ser Ser Gly Thr Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Pro Phe Pro Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110

Thr Val Ser Ser Gly Asp Gly Ser Ser Gly Gly Ser Gly Gly Ala Ser
115 120 125

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
130 135 140

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
145 150 155 160

Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
165 170 175

Ile Tyr Tyr Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
180 185 190

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
195 200 205

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Gly Arg Ile Pro
210 215 220

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ser Gly Gly Ser
225 230 235 240

Gly Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu
245 250 255

Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn
260 265 270

Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln
275 280 285

Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly

290

295

Ser Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp
305 310 315 320

Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser
325 330 335

Pro Ser Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Glu Ser Ser
340 345 350

Arg Arg Gly Gly Cys
355